/ Active, not recruiting临床3期 Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) less than 6 years with severe hemophilia A (FVIII less than 1%) - BAX855 PUP
/ Active, not recruiting临床3期 A Phase 3, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors
/ Active, not recruiting临床4期 Phase IV Multi-center, Prospective, Interventional, Post-marketing study in Hemophilia B Patients in India receiving RIXUBIS as on-demand or Prophylaxis under standard clinical practice - None
100 项与 Baxalta Bioscience India Pvt Ltd. 相关的临床结果
0 项与 Baxalta Bioscience India Pvt Ltd. 相关的专利（医药）
100 项与 Baxalta Bioscience India Pvt Ltd. 相关的药物交易
100 项与 Baxalta Bioscience India Pvt Ltd. 相关的转化医学
